1837 ET - CSL's downgrade to FY 2026 earnings revenue and profit guidance didn't surprise Jefferies much. That's because issues affecting immunoglobulin in the U.S. and albumin in China were already known. "We continue to believe both markets are underpenetrated, so the industry should grow over the medium term," says analyst David Stanton. The focus now is whether CSL can signal to investors what its net profit is likely to be in FY 2027 and FY 2028. "Given medium-term market growth and CSL's cost-out program progression, we are at mid-single-digit constant currency net profit growth for FY 2027 and FY 2028," Jefferies says. It retains a buy call, while lowering its price target by 8% to A$195.00 a share. CSL ended Monday at A$100.75. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

May 11, 2026 18:37 ET (22:37 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.